Summary Safety Review - Hydroxyzine (ATARAX and generics) - Assessing the Potential Risk of Abnormal Heart Rhythm
A safety review was undertaken soon after the European Medicines Agency notified Health Canada of the possibility that the use of hydroxyzine products could be associated with abnormal changes in the electrical activity of the heart, such as QT interval prolongation.
- Publisher - Current Organization Name: Health Canada
- Licence: Open Government Licence - Canada
Data and Resources
Similar records